The purpose of this shared resource is to provide human tissues, biological fluids, and expert pathologic interpretation for investigators in all of the projects under the direction of expert pathologists. The Histopathology and Tissue/Biologic Fluids Resource has been in existence since 1986 and expanded under the support of the GI SPORE. As of this year, the Resource includes 1698 banked colorectal carcinoma resection specimens, 354 colorectal adenoma samples, 325 hepatic metastases of colorectal carcinoma, 1013 pancreatic carcinoma specimens, 588 xenografts of colorectal carcinoma, 101 pancreatic carcinoma xenografts, 5298 blood specimens from individuals at risk for colorectal carcinoma, and 867 blood specimens from patients with pancreatic carcinoma. Formalin-fixed paraffin-embedded tissues, frozen materials and clinical and outcome data are available for the vast majority of resection specimens. Most recently, this resource has expanded its collections to include high quality snap frozen and formalin fixed samples of end stage pancreatic or colorectal cancer from 120 rapid autopsy participants. 133 tissue microarrays of colorectal and pancreatic neoplasms and diseases have been created. Eight fully characterized pancreatic carcinoma cell lines have been prepared from human tumors and shared with the ATCC. The biospecimens are harvested and banked in accordance with the National Cancer Institute's Best Practice Guidelines for Biorepositories. Distribution of these specimens to SPORE investigators has resulted in over 100 publications. This Core procures additional xenografts, fresh frozen colorectal and pancreatic neoplasms and blood and pancreatic juice samples, and provides expert pathologic consultation to investigators. Specimens are collected under the supervision of pathologists with expertise in colorectal and pancreatic neoplasia in close collaboration with clinical specialists in these areas and in similarly close collaboration with basic research investigators to maximize translational impact of the projects. Clinical and family histories are entered into a password protected web-based tracking system for our pancreatic cases. This Web-based interface follows the recommendations of the National Research Council, and includes user authentication, encryption, audit trails, and disaster recovery. A mechanism is in place for prioritization of distribution of requested resources to investigators within and external to the Johns Hopkins GI Cancer SPORE. Biosamples have been shared with investigators at over 50 other institutions. Collaboration with investigators at other centers fosters the accrual of rare tumor types.

Public Health Relevance

Neoplasms of the pancreas and colon are among the most common causes of cancer related death in the United States. This core resource will thus support the projects of this application related to the diagnosis and treatment of pancreatic and/or colorectal neoplasia with high quality tissues and biosamples.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA062924-19
Application #
8366075
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
1997-02-28
Project End
2017-08-31
Budget Start
2012-09-19
Budget End
2013-08-31
Support Year
19
Fiscal Year
2012
Total Cost
$124,978
Indirect Cost
$47,832
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Llosa, Nicolas J; Cruise, Michael; Tam, Ada et al. (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5:43-51
Eshleman, James R; Norris, Alexis L; Sadakari, Yoshihiko et al. (2015) KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol 13:963-9.e4
Zhen, David B; Rabe, Kari G; Gallinger, Steven et al. (2015) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 17:569-77
Patel, Kalpesh; Iacobuzio-Donahue, Christine A; Gormley, Paul E et al. (2015) Are we systematically under-dosing patients with fluorouracil? J Clin Oncol 33:e36-7
De Remigis, Alessandra; de Gruijl, Tanja D; Uram, Jennifer N et al. (2015) Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer 136:127-37
Sutcliffe, Catherine G; Schultz, Kathleen; Brannock, Julitta M et al. (2015) Do people know whether they are overweight? Concordance of self-reported, interviewer-observed, and measured body size. Cancer Causes Control 26:91-8
Black, Chelsea M; Armstrong, Todd D; Jaffee, Elizabeth M (2014) Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res 2:307-19
Kojima, Masatsugu; Murata, Satoshi; Mekata, Eiji et al. (2014) Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine. J Immunother 37:147-54
Wu, Xinyan; Renuse, Santosh; Sahasrabuddhe, Nandini A et al. (2014) Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nat Commun 5:4961
Amato, Eliana; Molin, Marco Dal; Mafficini, Andrea et al. (2014) Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 233:217-27

Showing the most recent 10 out of 633 publications